porphyra 334 oligopeptide-180 hamilelikte güvenli mi?

Related ingredients

Frequently asked questions

porphyra 334 oligopeptide-180 hamilelikte güvenli mi?

No harmonised CLP (ECHA Annex VI) reproductive classification, no SCCS or CIR safety assessment indicating reproductive hazard, and no peer‑reviewed evidence of reproductive toxicity for Porphyra‑334 or its peptide conjugates in the literature searched (PubMed, PubChem, CosIng). Therefore default hazard/mechanism scores are 0; dermal exposure from a high‑molecular‑weight peptide/MAA conjugate is expected to be negligible for adults (sources: PubMed, PubChem, CosIng, ECHA Annex VI).

porphyra 334 oligopeptide-180 emzirirken güvenli mi?

Same rationale as pregnancy: no regulatory flags (ECHA Annex VI), no CIR/SCCS adverse findings, and no peer‑reviewed evidence of transfer into milk or systemic toxicity for Porphyra‑334 conjugates. Expected adult dermal absorption negligible, so breastfeeding exposure from topical use is expected to be negligible (PubMed, PubChem, CosIng).

porphyra 334 oligopeptide-180 bebek cildi için güvenli mi?

Hazard and mechanism unchanged (no evidence of reproductive/toxic effects). Adult dermal absorption is considered negligible for this large peptide/MAA conjugate; however, infant skin has higher permeability — per instruction, exposure score increased by +1 for 0–3 yr (adult e=0 → infant e=1). No infant‑specific toxicity data located (PubMed, CosIng).

VeriMom porphyra 334 oligopeptide-180 nasıl puanlıyor?

VeriMom porphyra 334 oligopeptide-180'yi EU CosIng, ECHA sınıflandırmaları ve PubMed çalışmalarına göre 100/100 (bilinen risk yok) olarak puanlar.

Hamilelikte porphyra 334 oligopeptide-180 yerine neler kullanılabilir?

Benzer işlevli ve bilinen riski olmayan alternatifleri içeren listemize bakın.